Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas
(2002) In Läkartidningen 99(5). p.407-410- Abstract
- The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1124940
- author
- Ridderstråle, Martin LU and Groop, Leif LU
- organization
- alternative title
- A case report. Rosiglitazone treatment was highly effective yet had to be terminated
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Läkartidningen
- volume
- 99
- issue
- 5
- pages
- 407 - 410
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:11881246
- scopus:0037204317
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- 8049f080-38d8-468b-8db8-66703e6fec5e (old id 1124940)
- alternative location
- http://ltarkiv.lakartidningen.se/artNo24143
- date added to LUP
- 2016-04-01 16:59:42
- date last changed
- 2024-05-10 14:50:19
@article{8049f080-38d8-468b-8db8-66703e6fec5e,
abstract = {{The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.}},
author = {{Ridderstråle, Martin and Groop, Leif}},
issn = {{0023-7205}},
language = {{swe}},
number = {{5}},
pages = {{407--410}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas}},
url = {{http://ltarkiv.lakartidningen.se/artNo24143}},
volume = {{99}},
year = {{2002}},
}